Published: 19:03, October 19, 2021 | Updated: 18:00, October 22, 2021
Stepping into 20th year of innovation, HKSTP looks to GBA
By Zeng Xinlan

The iconic Charles K Kao Auditorium stands among buildings in Hong Kong Science Park. The Science Park is a hub for innovation in the city. (JUSTIN CHIN / BLOOMBERG)

Riding the wave of opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area, Hong Kong Science and Technology Parks Corp aims to elevate Hong Kong’s innovation and technology through re-industrialization and by nurturing future professionals, HKSTP said as it kickstarted celebrations for 20th anniversary on Tuesday.

“Our new vision will capture emerging GBA opportunities to ensure innovation translated to success, spark a future of revitalized industrial and new industries, while also develop the critical skills and talent for tomorrow,” CEO Albert Wong Hak-keung said.

The Hong Kong Science and Technology Parks Corp said it is dedicated to being a gateway between the Chinese mainland and overseas markets

ALSO READ: HKEX, HKSTP sign MOU on biotech, fintech initiatives

Leveraging its advantages of internationalization and top-notch basic science research capacity in areas such as medical research and fintech, HKSTP said it is dedicated to being a gateway between the Chinese mainland and overseas markets, introducing tech companies in the mainland and in Hong Kong to the world while attracting foreign professionals and investments.

The company said it will move ahead with innovation and technology collaborations between Hong Kong and Shenzhen through its “GBA InnoExpress” program, a one-stop service platform helping companies expand into the GBA, and its “GBA InnoAcademy” program, which aims to nurture and attract next-generation tech talent to the city.

To accelerate the commercialization process from biotech research, HKSTP launched in October the “HKSTP Institute for Translational Research”, or ITR, to spearhead the translation of biomedical technologies to benefit the public and the companies.

The process of bringing biomedical technologies from discovery to the market is long, risky and expensive, but the risks decrease as the companies advance from the research to the clinical phase, said John Kao, the head of ITR.

READ MORE: HKSTP showcases HK's I&T strengths in Japan

Hong Kong has an edge with the right skills, a mature financing channel, and an advanced infrastructure and connectivity to the mainland and overseas markets to become a preeminent hub for translational research and development, he added.

HKSTP has nurtured over 1,000 startups and has a research team of over 11,000 professionals.


xinlanzeng@chinadailyhk.com